Aprotinin Exerts Differential and Dose-Dependent Effects on Myocardial Contractility, Oxidative Stress, and Cytokine Release After Ischemia-Reperfusion

Annals of Thoracic Surgery

Volumn 86, Issue 2, 2008, Pages 568-575

  McEvoy, Matthew D ^a   Taylor, Anna Greta ^a   Zavadzkas, Juozas A ^b   Mains, Ira M ^b   Ford, Rachael L ^b   Stroud, Robert E ^b   Jeffords, Laura B ^b   Beck, Christy U ^b   Reeves, Scott T ^a   Spinale, Francis G ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; INTERLEUKIN 6; MYELOPEROXIDASE; TROPONIN I; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZATION; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; SYSTOLE;

ANIMALS; APROTININ; CARDIAC SURGICAL PROCEDURES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTICITY; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERLEUKIN-6; MICE; MICE, INBRED STRAINS; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATIVE STRESS; PEROXIDASE; SERINE PROTEINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 47149110257     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.04.025     Document Type: Article

References (27)

1. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
2. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
3. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
4. Bull D.A., and Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 75 Suppl (2003) 735-739
5. Tassani P., Augustin N., Barankay A., Braun S.L., Zaccaria F., and Richter J.A. High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 14 (2000) 682-686
6. Englberger L., Kipfer B., Berdat P.A., Nydegger U.E., and Carrel T.P. Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response?. Ann Thorac Surg 73 (2002) 1897-1904
7. Khan T.A., Bianchi C., Voisine P., et al. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 128 (2004) 602-608
8. Lazar H.L., Bao Y., Tanzillo L., et al. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 20 (2005) 519-523
9. Royston D., Cardigan R., Gippner-Steppert C., and Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen?. Anesth Analg 92 (2001) 830-836
10. van Oeveren W., Jansen N.J., Bidstrup B.P., et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44 (1987) 640-645
11. Creemers E.E., Davis J.N., Parkhurst A.M., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284 (2003) H364-H371
12. Ikonomidis J.S., Hendrick J.W., Parkhurst A.M., et al. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288 (2005) H149-H158
13. Suga H., and Sagawa K. Mathematical interrelationship between instantaneous ventricular pressure-volume ratio and myocardial force-velocity relation. Ann Biomed Eng 1 (1972) 160-181
14. McCarthy RJ, Tuman KJ, O'Connor C, Ivankovich AD. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs. Anesth Analg 199989:1096-100.
15. Khan T.A., Bianchi C., Voisine P., et al. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 128 (2004) 602-608
16. Beath S.M., Nuttall G.A., Fass D.N., Oliver Jr. W.C., Ereth M.G., and Oyen L.J. Plasma aprotinin concentrations during cardiac surgery: full- versus half-dose regimens. Anesth Analg 91 (2001) 257-264
17. Prabhu S.D. Cytokine-induced modulation of cardiac function. Circ Res 95 (2004) 1140-1153
18. Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65 (2003) 81-101
19. Srour N., Lebel A., McMahon S., et al. TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett 554 (2003) 275-283
20. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 53 (2002) 31-47
21. Dewald O., Frangogiannis N.G., Zoerlein M., et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci USA 100 (2003) 2700-2705
22. Vasilyev N., Williams T., Brennan M.L., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112 (2005) 2812-2820
23. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., and Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158 (2001) 879-891
24. American Heart Association Advisory: Bayer suspends marketing of aprotinin (Trasylol) at FDA request, November 2007. http://www.informz.net/heart/archives/archive_518051.html Accessed December 2007
25. Han S.N., and Meydani S.N. Antioxidants, cytokines, and influenza infection in aged mice and elderly humans. J Infect Dis 182 Suppl 1 (2000) 74-80
26. Vallejo J.G., Nemoto S., Ishiyama M., et al. Functional significance of inflammatory mediators in a murine model of resuscitated hemorrhagic shock. Am J Physiol Heart Circ Physiol 288 (2005) H1272-H1277
27. Diwan A., Dibbs Z., Nemoto S., et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 109 (2004) 262-268